Safety and Efficacy of Adjunctive Intra-arterial Tenecteplase following Successful Thrombectomy in Patients with Large Vessel Occlusion: A Phase 1/2 Randomized Clinical Trial

特奈特普酶 医学 随机对照试验 闭塞 临床试验 心脏病学 内科学 溶栓 心肌梗塞
作者
Xianhua Hou,Jiacheng Huang,Changwei Guo,Li Wang,Yuxuan He,Chen Lin,Qu Liu,Junhua Wu,Min Wu,Thanh N. Nguyen,Raul Nogueira,Duolao Wang,Jeffrey L. Saver,Wenjie Zi,Zhenhua Zhou
出处
期刊:Cold Spring Harbor Laboratory - medRxiv 被引量:1
标识
DOI:10.1101/2024.11.17.24317449
摘要

Abstract Background Adjunct intra-arterial thrombolysis has been shown to potentially improve clinical outcomes in patients with large vessel occlusion (LVO) stroke who have undergone successful endovascular thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin specificity and extended activity duration, may be a better choice than alteplase for intra-arterial thrombolysis. However, the optimal dose, safety and efficacy of intra-arterial tenecteplase remain unclear. Objective To evaluate the optimal dose, safety and efficacy of adjunctive intra-arterial tenecteplase following successful EVT in LVO patients. Methods and design This study is a two-part, phase Ib/IIa, multicenter, open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II) trial conducted in China involving patients LVO patients who achieved successful EVT (defined as the expanded Thrombolysis in Cerebral Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known well. In Part Ib, the dose escalation will be conducted in up to four tiers of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of 0.1875mg/kg, and the primary outcome is symptomatic intracranial hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized among two selected safe doses and a placebo, and the primary outcome will be the proportion of patients with nondisabled outcome (modified Rankin Scale score of 0 to 1) at 90 days. Discussions This pivotal trial will provide important data on adjunctive intra-arterial tenecteplase following successful EVT in patients with acute ischemic stroke due to LVO and may support advance of treatment standards. Trial registry number ChiCTR2300073787 and ChiCTR2400080624 ( www.chictr.org.cn ).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yangyanan的应助被林中鸟采纳,获得10
刚刚
清晨的小鹿完成签到,获得积分10
刚刚
111发布了新的文献求助10
刚刚
刚刚
coco发布了新的文献求助10
1秒前
充电宝的应助被冷傲的罡采纳,获得10
1秒前
Emma完成签到,获得积分10
1秒前
鱼鹰发布了新的文献求助30
1秒前
childe发布了新的文献求助10
1秒前
天真的日记本完成签到,获得积分10
2秒前
2秒前
朝阳完成签到,获得积分10
2秒前
赵晓宇完成签到,获得积分10
2秒前
从容水壶发布了新的文献求助10
3秒前
柒零完成签到,获得积分10
3秒前
czephyr完成签到,获得积分10
3秒前
在水一方的应助被张凯文采纳,获得10
3秒前
透明的世界的应助被BUT采纳,获得10
3秒前
臭小子发布了新的文献求助30
4秒前
haha完成签到,获得积分10
5秒前
觅海完成签到 ,获得积分10
5秒前
5秒前
干净雪卉完成签到 ,获得积分10
5秒前
6秒前
6秒前
6秒前
冷酷的依瑶的应助被易123采纳,获得10
7秒前
molihuakai的应助被鲸落采纳,获得10
7秒前
秋风的应助被任性的皮卡丘采纳,获得10
7秒前
青歌发布了新的文献求助10
7秒前
炫彩小陈完成签到,获得积分10
7秒前
gzsy完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
陌生人儁发布了新的文献求助10
7秒前
顺利的丹妗完成签到 ,获得积分10
8秒前
8秒前
8秒前
苏西yy发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317